SPY326.54-3.44 -1.04%
DIA265.06-1.53 -0.57%
IXIC10,911.59-274.00 -2.45%

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of

· 10/13/2020 07:01

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
  • Session: D1T03.3C: Late-Breaking News Session
  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/